FABRICATION OF MICROEMULSION LOADED SUBLINGUAL FILM FOR RAPID ABSORPTION OF FENTANYL CITRATE IN TRANSIENT BREAKTHROUGH PAIN

  • D. MUNDHEY Centre for Advanced Research and Innovation (CARIn), Zim Laboratories Ltd. B-21/22, MIDC Area, Kalmeshwar 441501 Dist. Nagpur (M. S.), India
  • N. SAPKAL Gurunanak College of Pharmacy, Nari, Kamgarnagar, Nagpur (M. S.), India
  • A. DAUD Centre for Advanced Research and Innovation (CARIn), Zim Laboratories Ltd. B-21/22, MIDC Area, Kalmeshwar 441501 Dist. Nagpur (M. S.), India

Abstract

Objective: The present research work aims to develop a microemulsion loaded sublingual film for rapid absorption of fentanyl citrate in transient breakthrough pain.


Methods: The Fentanyl citrate microemulsion loaded sublingual film was prepared using Capmul MCM C8 (oil), tween 20 (surfactant) and propylene glycol (co-surfactant) with different grades of film-forming polymer (HPMC) using a film casting machine. The films were evaluated for in vitro disintegration study, tensile strength, folding endurance, content uniformity, drug content, in vitro dissolution, pH, thickness and weight variation, scanning electron microscopy, ex vivo permeation study, droplet size, polydispersity index, zeta potential, % moisture content and stability study were evaluated.


Results: The optimized film formulation showed desired mechanical properties (tensile strength of 0.291 kg/cm2) and a minimum disintegration time of 20 s. The optimized sublingual film formulation exhibited 43.16 % of FC microemulsion loading. Morphological study showed the absence of drug crystals on the polymeric surface. Permeation studies through goat sublingual mucosa indicated 89% fentanyl citrate release through fentanyl citrate microemulsion loaded sublingual film, whereas only 40% fentanyl citrate release was obtained when it was directly added to film without microemulsion strategy.


Conclusion: The present study indicated that extend of permeation of fentanyl citrate when added to the sublingual film in microemulsion form was around 2.225 folds higher than when added directly to film without microemulsion. The present microemulsion embedded film technology could be a promising alternative to conventional drug delivery systems and traditional routes of administration for breakthrough pain management.

Keywords: Fentanyl citrate, Microemulsion, Sublingual film

References

1. Roy SD, Flynn GL. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 1988;5:580-6.
2. Gardner Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage 2001;22:627–30.
3. McMillan C. Breakthrough pain: assessment and management in cancer patients. Br J Nurs 2001;10:860–6.
4. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
5. Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001;15:323–8.
6. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41:661–80.
7. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10:373–88.
8. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytrochrome P450 3A4: implication for interindividual variability in disposition efficacy and drug interactions. Drug Metab Dispos 1997;25:1072–80.
9. Allan L, Hays H, Jensen NH, De Waroux BL, Bolt M, Donald R. Randomised crossover trial of transdermal fentanyl and sustained-release oral morphine for treating chronic noncancer pain. Br Med J 2001;322:1154–8.
10. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2001;2:165–72.
11. Mather LE, Woodhouse A, Ward ME, Stephen J, Farr JS, Rubsamen AR. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol 1998;46:37–43.
12. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients’ perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157–60.
13. Blick SKA, Wagstaff AJ. Fentanyl buccal tablets in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006;66:2387–93.
14. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010;11:1017–23.
15. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343–50.
16. Stanley TH, Hague B, Mock DL, Streisand JB, Bubbers S, Dzelzkalns RR. Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers. Anesth Anal 1989;69:21–7.
17. Christie J, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238–45.
18. Streisand JB, Varvel JR, Stanski DR, Le Maire L, Ashburn MA, Hague BI. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991;75:223–9.
19. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303–12.
20. Lim SCB, Paech M, Sunderland VB, Roberts M, Banks S, Rucklidge M. Pharmacokinetics of nasal fentanyl. J Pharm Prac Res 2003;33:59–63.
21. Mercadante S, Radbruck L, Davies A, Poulain P, Sitte T, Perkins P. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin 2009;25:2805–15.
22. Kaasa S, Moksnes K, Nolte T, Lefebvre Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manage 2010;6:17–26.
23. Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ, Wallenstein S. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-42.
24. Bredenberg S, Duberg M, Lennernas B, Lennernas H, Pettersson A, Westerberg M. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Euro J Pharm Sci 2003;20:327–34.
25. Lennernas B, Frank Lissbrant I, Lennernas H, Kalkner KM, Derrick R, Howell J. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010;24:286–93.
26. Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001;15:323–8.
27. Jangipuria F, Londhe V. Solubility enhancement of lurasidone hydrochloride by preparing SMEDDS. Int J Pharm Pharm Sci 2015;7:283-8.
28. Mauludin R, Mohamad SF, Suciati T. Formulation and characterization of ascorbyl palmitate loaded o/w microemulsion. Int J Pharm Pharm Sci 2014;6:294-8.
29. Tiwari RR, Umashankar MS, Damodharan N. Recent update on oral films: a bench to market potential. Int J Appl Pharm 2018;10: 27-33.
30. Nafee NA, Boraie NA, Ismail FA, Mortada LM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm 2003;53:199-212.
31. Gould K, Desai H, Kumar TMP. Preparation and evaluation of novel buccal adhesive system. AAPS PharmSciTech 2004;5:1-9.
32. Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: a modern expansion in drug delivery system. Saudi Pharm J 2015;24:537-46.
33. Fentanyl citrate Injection. United States Pharmacopoeia 30 National Formulary 25 (USP-NF) The Official Compendia of Standards United States Pharmacopeial Convention; 2014.
34. United States Food and Drug Administration (US FDA) Fentanyl citrate Dissolution Database. Available from: https://www.accessdata.fda.gov› Drug Databases › Dissolution Methods [Last accessed on 21 Apr 2017]
35. Kumar GP, Phani AR, Prasad RG, Sanganal JS, Manali N, Gupta R. Polyvinylpyrrolidone oral films of enrofloxacin: Film characterization and drug release. Int J Pharm 2014;471:146–52.
36. Kaur G, Singh D, Brar V. Bioadhesive okra polymer-based buccal patches as a platform for controlled drug delivery. Int J Biol Macromol 2014;70:408–19.
37. Govindasamy P, Kesavan BR, Narasimha JK. Formulation of unidirectional release buccal patches of carbamazepine and study of permeation through porcine buccal mucosa. Asian Pac J Trop Biomed 2013;3:995-1002.
38. Darwish MK, Elmeshad AN. Buccal mucoadhesive tablets of flurbiprofen: characterization and optimization. Drug Discovery Ther 2009;3:181–9.
39. Nidhin M, Indumathy R, Sreeram KJ. Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. Bull Material Sci 2008;31:93–6.
40. Kumar R, Sinha VR. Preparation and optimization of vornicazole microemulsion for ocular delivery. Colloids Surfaces B 2014;117:82–8.
41. Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT. The intracellular effect of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 2009;30:374-82.
Statistics
15 Views | 10 Downloads
Citations
How to Cite
MUNDHEY, D., SAPKAL, N., & DAUD, A. (2021). FABRICATION OF MICROEMULSION LOADED SUBLINGUAL FILM FOR RAPID ABSORPTION OF FENTANYL CITRATE IN TRANSIENT BREAKTHROUGH PAIN. International Journal of Applied Pharmaceutics, 13(3), 233-238. https://doi.org/10.22159/ijap.2021v13i3.40744
Section
Original Article(s)